Myriad Genetics Fiscal ThirdQuarter 2016 Earnings Call 05032016

  • Slides: 22
Download presentation
Myriad Genetics Fiscal Third-Quarter 2016 Earnings Call 05/03/2016 1 Copyright © 2016 2015 Myriad

Myriad Genetics Fiscal Third-Quarter 2016 Earnings Call 05/03/2016 1 Copyright © 2016 2015 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com.

Forward Looking Statements Non-GAAP Financial Measures Some of the information presented here today may

Forward Looking Statements Non-GAAP Financial Measures Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10 -K, its quarterly reports on Form 10 -Q, and its current reports on Form 8 -K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forwardlooking statements. In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company’s financial measures under GAAP include substantial onetime charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below. Fiscal Year 2016 GAAP diluted earnings per share Acquisition – amortization of intangible assets Non-GAAP diluted earnings per share For additional information on GAAP to non-GAAP reconciliation see: https: //www. myriad. com/investors/gaap-to-non-gaap-reconciliation/ Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. $1. 48 - $1. 50 $0. 15 $1. 63 - $1. 65 2

Third Quarter Results Exceed Expectations Q 3 FY 16 Actual Results Yo. Y Growth

Third Quarter Results Exceed Expectations Q 3 FY 16 Actual Results Yo. Y Growth $190. 5 M 6% Adjusted EPS $0. 41 3% GAAP EPS $0. 44 27% Revenue 3 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 3

Hereditary Cancer Revenue Remains Stable Hereditary Cancer Revenue ($ in mil. ) $175 $150

Hereditary Cancer Revenue Remains Stable Hereditary Cancer Revenue ($ in mil. ) $175 $150 $125 3 Q 16 2 Q 16 1 Q 16 4 Q 15 3 Q 15 2 Q 15 1 Q 15 $100 4 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 4

Expanding Advantage in Variant Classification Number of Variants 100, 000 80, 000 Pheno™ Mu.

Expanding Advantage in Variant Classification Number of Variants 100, 000 80, 000 Pheno™ Mu. Co™ 3 D Structural Analysis Lit. VIEW™ in. SITE™ 60, 000 40, 000 20, 000 0 Myriad Before my. Risk BRCA Mutations (MYGN) Myriad Today Colaris Myriad in FY 20 my. Risk Other Genes 5 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 5

Updated NCCN Treatment Recommendations Genes Change in NCCN Treatment Recommendations PALB 2 Consider a

Updated NCCN Treatment Recommendations Genes Change in NCCN Treatment Recommendations PALB 2 Consider a prophylactic mastectomy for patients with deleterious mutations BRIP 1, RAD 51 C, RAD 51 D Consider a prophylactic oophorectomy for patients with deleterious mutations 6 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 6

Mutation Rates Support Testing Patients Under 60 Rate of Deleterious Mutations 20. 0% Mutation

Mutation Rates Support Testing Patients Under 60 Rate of Deleterious Mutations 20. 0% Mutation Rate Unchanged Current Guidelines 10. 0% 25 -29 30 -34 35 -39 BRCA 1/2 40 -44 45 -49 Other Breast Cancer Genes 50 -54 55 -59 60 -64 Other Panel Genes 7 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 65 -69 7

Preventive Care Oncology Hereditary Cancer Market Expansion Progress Indication Added Market Potential Colon Cancer

Preventive Care Oncology Hereditary Cancer Market Expansion Progress Indication Added Market Potential Colon Cancer @ 5% Mutation Risk +$100 M 50% All Endometrial Cancer +$150 M 50% Breast Cancer <60 yrs +$150 M FY 17 FY 18 All Pancreatic Cancer +$125 M Partial FY 17 Prostate Cancer +50 M FY 17 Colon Cancer Asymptomatic Market + $18 B (6 M patients) 50% Guidelines Contracting 8 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 8

New Product Pipeline Market Opportunity > $1 B Reimbursed TAM Vectra DA Prolaris Companion

New Product Pipeline Market Opportunity > $1 B Reimbursed TAM Vectra DA Prolaris Companion Diagnostics my. Path Melanoma my. Plan Lung Cancer $0. 0 $1. 0 $2. 0 $3. 0 $4. 0 $5. 0 $6. 0 (in billions) Currently Reimbursed Market Opportunity Total Market Opportunity 9 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 9

Vectra DA Volumes Grow 18% Year-Over-Year 18% Yo. Y Volume Growth 17% Yo. Y

Vectra DA Volumes Grow 18% Year-Over-Year 18% Yo. Y Volume Growth 17% Yo. Y Revenue Growth 36, 000 tests $10. 5 mil. 42, 500 tests $12. 3 mil. $13 40 $12 30 $11 20 $10 FY 15 Q 1 FY 15 Q 2 FY 15 Q 3 Volume in 000’s FY 15 Q 4 FY 16 Q 1 FY 16 Q 2 FY 16 Q 3 Revenue 10 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. Revenue in Millions Volume in 000’s 50 10

First Two Private Payer Contracts for Vectra DA U. S. Vectra DA Insurance Coverage

First Two Private Payer Contracts for Vectra DA U. S. Vectra DA Insurance Coverage (42%) Medicare 1. 5 million RA patients Signed first two commercial payer contracts representing two million lives Commercial Insurers Medicare Private Covered Private Non-Covered 11 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 11

Prolaris Volumes Grow 90% Year-Over-Year 90% Yo. Y Volume Growth 5000 4, 300 tests

Prolaris Volumes Grow 90% Year-Over-Year 90% Yo. Y Volume Growth 5000 4, 300 tests 2, 250 tests $4 $3. 2* 3000 $3 $1. 9 2000 $2 1000 $1 0 $0 1 Q 15 2 Q 15 3 Q 15 Volume 4 Q 15 1 Q 16 Revenue 2 Q 16 3 Q 16 *Excludes Medicare retrospective claim revenue 12 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. Revenue in Millions Prolaris Volume 4000 $5 12

Significant Private Payer Progress With Prolaris U. S. Prolaris Insurance Coverage (36%) Favorable Intermediate

Significant Private Payer Progress With Prolaris U. S. Prolaris Insurance Coverage (36%) Favorable Intermediate 200, 000 localized prostate cancer patients Medicare 28 million commercial lives under coverage Commercial Insurers Private Covered Private Non-Covered Medicare Non-Covered 13 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 13

Prolaris and my. Plan Renal Cancer Predict Most Important Clinical Endpoints 16. 9% 41.

Prolaris and my. Plan Renal Cancer Predict Most Important Clinical Endpoints 16. 9% 41. 0% Study of 440 cancer patients with Gleason score ≤ 6 Study of 262 renal carcinoma patients 8 x Risk 6. 5% 2. 2% 3 x Risk 10 -Year Disease Specific Mortality Low Prolaris Score 5. 3% 8 x Risk 2. 0% Biochemical Recurrence 5 -Year Disease Specific Mortality High Prolaris Score Low my. Plan Renal Score High my. Plan Renal Score 14 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 14

Completing my. Path Melanoma Reimbursement Dossier my. Path Melanoma Diagnostic Accuracy 100% 90% my.

Completing my. Path Melanoma Reimbursement Dossier my. Path Melanoma Diagnostic Accuracy 100% 90% my. Path Melanoma Clinical Utility 100% 92% 80% 75% n=218 patients 60% Favorable outcomes study to be presented 40% 50% 41% 38% 22% 25% 20% 11% 9% 0% Validation 1 Validation 2 n=437 patients n=736 patients Validation 3 0% Indeterminate Malignant Pre-Test Benign Post-Test 15 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 15

Complete Suite of Companion Dx for PARP Inhibitors Sample Blood Tumor Panel Immune Pathway

Complete Suite of Companion Dx for PARP Inhibitors Sample Blood Tumor Panel Immune Pathway Tumor 80+ clinically actionable oncology genes identified by pharma partners Pathway test to identify responders to immunotherapy Biomarkers BRCA 1&2 Tumor BRCA 1&2 Genome-wide assessment of DNA scar associated with DNA repair defects Intellectual Property Database, process, bioinformatics MYGN has IP on three proprietary technologies (LOH, TAI, LST) Database, process, bioinformatics Patent filed CE Marked Early access launch for platinum In research use with major pharma partners Currently Marketed FDA approved 16 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 16

BIPOLAR DISORDER MAJOR DEPRESSIVE DISORDER 96% Assay Score AUC in Training Set -3 •

BIPOLAR DISORDER MAJOR DEPRESSIVE DISORDER 96% Assay Score AUC in Training Set -3 • Multimarket proteomic assay run on Myriad-RBM Luminex platform • Consists of 18 protein analytes from blood • Discovery completed in 150 wellcharacterized BD 1 and MDD samples • Beginning enrollment in prospective validation study at three major medical centers; will enroll ≈ 300 patients +3 my. Path Bi. Polar Validation Study Enrollment Starting 17 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 17

International Revenue Improved to 5% of Total Sales Goal to have international product revenue

International Revenue Improved to 5% of Total Sales Goal to have international product revenue comprise 10% of sales by FY 20 International Product Revenue as a Percentage of Total Revenue 10% 8% 6% 4% 2% 0% Q 4 FY 10 Hereditary Cancer Q 3 FY 16 Kit CDx Q 4 FY 20 Clinic 18 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 18

Progress on Endo. Predict Reimbursement Reimbursed Total Addressable Market $300 $250 $200 Material increase

Progress on Endo. Predict Reimbursement Reimbursed Total Addressable Market $300 $250 $200 Material increase in reimbursed total addressable market outside the U. S. over the next two years $150 $100 $50 $0 Germany FY 16 France UK Italy FY 18 Switz. Canada 19 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 19

Fiscal Third-Quarter 2016 Revenue By Product (in millions) Product 3 Q 16 3 Q

Fiscal Third-Quarter 2016 Revenue By Product (in millions) Product 3 Q 16 3 Q 15 Yo. Y Growth Hereditary Cancer $156. 3 $159. 0 (2%) Vectra DA $12. 3 $10. 5 17% Prolaris $5. 2 $0. 5 940% Other $3. 6 $3. 0 20% Total Molecular Diagnostic Revenue $177. 4 $173. 0 3% Pharmaceutical & Clinical Services $13. 1 $7. 0 87% $190. 5 $180. 0 6% Total Revenue 20 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 20

Fiscal Third-Quarter Financial Results 3 Q 16 3 Q 15 Yo. Y Growth Total

Fiscal Third-Quarter Financial Results 3 Q 16 3 Q 15 Yo. Y Growth Total Revenue $190. 5 $180. 0 6% Gross Profit $150. 3 $143. 7 5% 78. 9% 79. 8% NA Operating Income $42. 6 $35. 7 19% Adjusted Operating Income $45. 8 $46. 3 (1%) Adjusted Operating Margin 24. 0% 25. 7% NA Net Income $32. 6 $21. 4 52% Diluted EPS $0. 44 $0. 29 52% Adjusted EPS $0. 41 $0. 40 3% (in millions except per share data) Gross Margin 21 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 21

4 Q 16 and FY 16 Financial Guidance Metric Fiscal Fourth-Quarter 2016 Fiscal Year

4 Q 16 and FY 16 Financial Guidance Metric Fiscal Fourth-Quarter 2016 Fiscal Year 2016 Revenue $186 to $188 million $753 to $755 million Diluted EPS $0. 32 to $0. 34 $1. 48 to $1. 50 Adjusted EPS $0. 36 to $0. 38 $1. 63 to $1. 65 22 Copyright © 2016 Myriad Genetics, Inc. , all rights reserved. www. Myriad. com. 22